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Abstract
Previously we have shown that insertion of IS1301 in the sia/ctr intergenic region (IGR) of serogroup C Neisseria meningitidis
(MenC) isolates from Spain confers increased resistance against complement-mediated killing. Here we investigate the
significance of IS1301 in the same location in N. meningitidis isolates from the UK. PCR and sequencing was used to screen a
collection of more than 1500 meningococcal carriage and disease isolates from the UK for the presence of IS1301 in the IGR.
IS1301 was not identified in the IGR among vaccine failure strains but was frequently found in serogroup B isolates (MenB)
from clonal complex 269 (cc269). Almost all IS1301 insertions in cc269 were associated with novel polymorphisms, and did
not change capsule expression or resistance to human complement. After excluding sequence types (STs) distant from the
central genotype within cc269, there was no significant difference for the presence of IS1301 in the IGR of carriage isolates
compared to disease isolates. Isolates with insertion of IS1301 in the IGR are not responsible for MenC disease in UK vaccine
failures. Novel polymorphisms associated with IS1301 in the IGR of UK MenB isolates do not lead to the resistance
phenotype seen for IS1301 in the IGR of MenC isolates.
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Introduction
The exclusively human pathogen Neisseria meningitidis causes
serious diseases including septicaemia and bacterial meningitis.
However, it is primarily a commensal of the human nasopharynx
in around 10% of healthy individuals [1,2]. Rarely, the bacterium
overcomes host defences, especially the complement system, and
causes bloodstream infection, septic shock and/or meningitis. The
meningococcus can express one of 13 capsules (classifying isolates
into serogroups) that are necessary for avoidance of complement-
mediated killing [3]. Isolates are also categorised into sequence
types (STs) based on sequences of seven housekeeping genes [4].
Most disease is caused by a limited number of genotypes, while
other genotypes seldom invade the bloodstream [5]. Clonal
complexes (cc) are groupings of STs with similar allelic profiles
typically sharing at least 4–5 loci (http://pubmlst.org/neisseria).
Recently we described a polymorphism in three serogroup C
ST-11 N. meningitidis isolates (MenC) from Spain that enhances
resistance against complement-mediated killing, the principal
mechanism of immunity against meningococcal disease [6]. In
all isolates, IS1301 was found in the 134 bp intergenic region
(IGR) between operons for capsule biosynthesis (sia) and export
(ctr) (Figure 1A), leading to up-regulation of capsule expression and
providing a generic mechanism for increased resistance against
bactericidal antibodies.
The MenC glycoconjugate vaccine has been very effective,
leading to .90% reduction of MenC cases in countries where it
has been introduced [7–10]. So far there has been no evidence of
emergence of strains that are resistant to the immune responses
elicited by the vaccine. However, there are a few reports of MenC
disease developing in subjects who have completed a course of
immunisation [11,12], and these could be caused by strains with
increased resistance to complement-mediated killing due to
insertion of IS1301 in the sia/ctr IGR. Furthermore, increased
resistance to complement-mediated killing conferred by IS1301
could promote meningococcal virulence. Here we investigate
whether isolates with IS1301 in the IGR are emerging among
vaccine failure strains, and compare its presence in UK carriage
and disease isolates.
Results
IS1301 in the IGR Is Not Associated with MenC Conjugate
Vaccine Failure in the UK
IS1301 in the sia/ctr IGR was originally described in MenC
isolates in Spain; isolates had low titre (,8) in serum bactericidal
assays (SBA) using sera from individuals immunised with the
MenC conjugate vaccine [6]. As an SBA titre of ,8 is a marker of
protective immunity [13,14], we examined MenC isolates from
individuals from the UK with meningococcal disease who had
completed a course of the MenC conjugate vaccine [11,15]. Most
isolates were ST-11 (79%; 26 out of 33, with the others were ST-
1095 [two isolates], ST-8, ST-2709, ST-467, ST-3463 and ST-
6331), the most common cause of MenC disease at the time of the
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IGR of any of the 33 MenC isolates, even though most isolates (32
out of 33) have IS1301 elsewhere in the genome (data not shown).
We also examined MenC disease isolates in the UK before the
introduction of the MenC conjugate vaccine (1998–99), and found
IS1301 in the IGR in less than 1% of the isolates (1 out of 104
isolates, Table 1); IS1301 was inserted at the same location but in
the opposite orientation (inverted) to the ST-11 isolates from Spain
[6]. Therefore, there is currently no evidence from the UK that
IS1301 in the IGR mediates a mechanism for escape from the
MenC conjugate vaccine.
Presence of IS1301 in the IGR of UK Meningococcal
Disease and Carriage Isolates
Enhanced resistance to human sera may promote the virulence
of N. meningitidis during infection, and therefore insertion of IS1301
in the IGR might be more frequent among meningococcal disease
compared to carriage isolates. We examined 741 carriage and 345
disease isolates of different serogroups collected between 1998 and
2000 in the South East of England (Table 1, [17,18]). In this
collection, insertion of IS1301 was significantly more frequent in
the IGR of disease (10%; 33 out of 345) compared to carriage
isolates (1.5%; 11 out of 741, p,0.0001, Table 1). Approximately
50% of the carriage isolates were unencapsulated (non-groupable),
and the presence/absence of IS1301 in the IGR should not affect
the phenotype of these isolates. To exclude this as a potential
confounding factor, we restricted our analysis to serogroupable
isolates. There was still a significant difference for the presence of
IS1301 in the IGR in disease (31 out of 336) compared to carriage
isolates (11 out of 365, p=0.0004) even after excluding
unencapsulated isolates.
Insertion of IS1301 was most frequently found in MenB isolates
belonging to clonal complex ST-269 (cc269) with 24 of 55 having
IS1301 in the IGR (Table 2). Cc269 causes a significant
proportion of meningococcal cases in UK [16,19], and in the
collection, cc269 isolates were more commonly found among
disease isolates (16%; 55 out of 345) compared to carriage isolates
(3%; 22 out of 741, p,0.0001). To account for this potential bias,
we analysed only cc269 isolates, and still found a significant
difference between the presence of IS1301 in the IGR of disease
isolates (44%; 24 out of 55) compared to carriage isolates (14%; 3
out of 22, p=0.017).
Figure 1. The intergenic region (IGR) between the operons for capsule transport (ctr) and biosynthesis (sia). A: The transcription
initiation site (Ti) is indicated [28] as well as the insertion of IS1301 in the IGR. The two most common polymorphic IGR with IS1301, IS-8 and iIS+69,
are also illustrated. B: Isogenic strains with and without the polymorphisms associated with IS1301 were constructed by tagging the nmb76 gene
downstream of the ctr operon with a kanamycin resistance (kan
R) cassette. C: The 8 bp deletion associated with IS1301 in the IGR; i) wild-type
sequence, and ii) to iv) shows the 8 bp deletion with associated base pair changes (indicated in bold and lower case). * Refers to the most common
type of IS-8, which was used for phenotypic analysis. The sequence denotes the base pairs from the insertion site of IS1301 up to the siaA
translational start (underlined).
doi:10.1371/journal.pone.0009413.g001
IS1301 in N. meningitidis
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Polymorphisms
Strikingly, only one of 44 IGRs with IS1301 identified among
isolates from South East England was identical to that in Spanish
MenC ST-11 isolates (Table 3). Most commonly IS1301 was
associated with an 8 bp deletion upstream of siaA (IS-8) or the IGR
contained an inverted IS1301 with an internal 69 bp duplication
(iIS+69); these two polymorphisms account for 66% (29 out of 44)
of the changes seen. The 8 bp deletion was accompanied by three
other sequence changes, one of which represented .80% of IS-8
(type (ii) in Figure 1C) and hence was chosen for further study. The
8 bp deletion is located 14 nucleotides upstream of siaA
translational start, and has been reported not to influence siaA
translation [20]. The 69 bp duplication within the inverted IS1301
duplicates bases 194 to 264 corresponding to nucleotides 580 to
649 of IS1301 in the original orientation [21].
Polymorphic sia/ctr IGRs with IS1301 Lead to Increased
Transcription of the Genes for Capsule Transport but Not
Capsule Biosynthesis
Insertion of IS1301 in the sia/ctr IGR of MenC isolates leads to
increased expression of the sia and ctr operons [6]. To investigate the
effect of IS1301 with associated polymorphisms, we constructed
isogenic strains by introducing the two common types of IGRs with
IS1301,I S - 8a n di I S +69, into a MenB cc269 strain. An antibiotic
resistance marker was inserted into nmb76 in strains containing these
polymorphisms (Figure 1B), and genomic DNA was used to transform
a MenB cc269 disease isolate (D157) without IGR changes;
transformants were selected with (IS-8+ and iIS+69+)a n dw i t h o u t
(IS-8- and iIS+69-) changes in the IGR. Compared with the effect of
IS1301 in MenC [6], both IS-8+ and iIS+69+ led to a similar two-fold
increase in the expression of ctrA as determined by qrtRT-PCR
(Figure 2A). However, no upregulation in siaA expression was detected
in these strains. The expression of siaA and ctrA in strains without
IS1301 in the IGR was similar to wild-type.
To verify the findings for siaA expression obtained by qrtRT-PCR,
we constructed lacZ translational sia f u s i o n si nM e n Bw i t hI G R s
without IS1301, and with the original IS1301, IS-8, or iIS+69. The
construct with IS1301 in the IGR showed a .30-fold increase in
Table 1. Presence of IS1301 in the IGR of UK disease and
carriage isolates from South East England.
Serogroup Disease Carriage P-value
a
Total + IS1301 Total + IS1301
B 209 30 (14%) 175 11 (6%) 0.01
C 104 1 (,1%) 16 0
W135 15 0 53 0
Y5 04 6 0
A1 00 0
X1 01 0 0
Z0 06 0
29E 1 0 70 0
NG
b 92 3 6 5 0
Total 345 33 (10%) 741 11 (1%) ,0.0001
aP-value was calculated using Fischer’s exact test.
bNG, non-groupable.
doi:10.1371/journal.pone.0009413.t001
Table 2. Presence of IS1301 in the IGR of MenB and MenC isolates from different clonal complexes.
Clonal complex MenB Disease MenB Carriage MenC Disease MenC Carriage
Total +IS1301 Total +IS1301 Total +IS1301 Total +IS1301
ST-41/44 complex/Lineage 3 94 1 (1%) 67 0 2 0 1 0
ST-269 55 24 (44%) 22 3 (14%) 2 0 2 0
ST-32 complex 18 2 (11%) 5 0 1 0 0 0
ST-11 complex 2 0 0 0 85 0 8 0
ST-35 3 0 16 0 0 0 1 0
S T - 4 6 1 30100000
S T - 1 0 3 10100000
ST-1157 1 0 3 0 0 0 0 0
ST-8 2 0 1 0 11 0 1 0
ST-60 9 1 (11%) 3 1 (33%) 0 0 0 0
S T - 3 7 10100000
S T - 3 6 4 20200000
S T - 2 2 10200000
ST-213 1 0 10 0 0 0 0 0
ST-18 3 0 0 0 2 1 (50%) 0 0
ST-162 1 0 10 0 0 0 0 0
S T - 1 6 7 10200000
S T - 2 5 4 00000010
Unassigned 11 1 (9%) 29 7 (24%) 1 0 2 0
Total 209 30 (14%) 175 11 (6%) 104 1 (,1%) 16 0
doi:10.1371/journal.pone.0009413.t002
IS1301 in N. meningitidis
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showed similar levels of b-galactosidase activity as the IGR without
changes (Figure 2B), consistent with the qrtRT-PCR results.
Increased Transcription of Capsule Transport Genes Does
Not Change the Amount of Capsule or Resistance against
Complement-Mediated Killing
It is not known whether increased expression of only capsule
transport genes is sufficient to increase capsule expression. FACS
analysis of the amount of capsule expressed by the strains IS-8+,
IS-8–, iIS+69+, iIS+69–, and D157 showed that strains with
polymorphic IGRs with IS1301 do not express increased amounts
of capsule compared to isogenic strains without the polymorphic
IGRs (Figure 3A). Although there was no detectable difference in
the amount of capsule, the novel polymorphic IGRs with IS1301
could still influence resistance against complement-mediated
killing. However, SBA titres were similar for strains with and
without the polymorphic IGRs with IS1301 (50% killing of all
strains was seen at a 1/512 dilution of human immune sera, not
shown). This was confirmed by human serum assays, in which
Table 3. Characteristics of IGRs with IS1301 in 44 MenB isolates from South East England.
IS iIS IS-8 iIS-8 IS+69 iIS+69 IS+72
D i s e a s e 151 4 4171
Carriage 0281000
Details of IS-8 and iIS+69 are shown in Fig. 1. iIS refers to IS1301 inserted in the IGR in the opposite orientation and +72 indicates IS1301 with an additional 72 bp
compared with Spanish ST-11 isolates.
doi:10.1371/journal.pone.0009413.t003
Figure 2. Expression of capsule biosynthesis genes. A: Relative levels of siaA (black bars) and ctrA (white bars) mRNA transcripts measured by
qrtRT-PCR. P,0.005 (*) for differences in ctrA mRNA levels in IS-8+ and iIS+69+ versus the controls, using Student’s t test. B: b-galactosidase activity
was determined for siaA translational fusions. C denotes a control without an IGR. Results are average of three independent experiments, and error
bars indicate the standard deviation (SD).
doi:10.1371/journal.pone.0009413.g002
IS1301 in N. meningitidis
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without IS1301 with associated polymorphisms (Figure 3B).
Presence of IS1301 in MenB cc269 Carriage and Disease
Isolates
Phenotypic analyses suggest that MenB IGR polymorphisms
might have no or little impact on meningococcal pathogenesis.
This is in contrast to our observation that the polymorphic IGRs
with IS1301 were more frequent in disease compared to carriage
isolates in the survey from South East England. IS1301 was
predominantly found among MenB cc269 isolates, of which only a
limited number were examined (55 disease and 22 carriage
isolates). We examined a larger number of MenB cc269 with 241
carriage isolates and 421 disease isolates from seven regions of the
UK. Consistent with the South East England isolates, insertion of
IS1301 in the IGR was significantly more frequent among disease
isolates (35%; 148 out of 421) compared to carriage isolates (26%;
63 out of 241, p,0.05). All IS1301 insertions in cc269 were
polymorphic and the majority (.80%; 178 out of 211) were IS-8
or iIS+69. Again when excluding non-groupable carriage isolates
from the analysis, there was still a significant difference between
the presence of IS1301 in the IGR of disease isolates (35%)
compared to carriage isolates (26%; 49 out of 187, p,0.05).
Next we extended our analysis to examine potential variation
within cc269. Some STs in the clonal complex are relatively
distant from the ancestral ST-269 and share only four out of seven
MLST loci with ST-269 (Figure 4); most of these STs (e.g. 1161
and 1163) cluster together around the subgroup-founder ST-275.
IS1301 in the IGR, or indeed anywhere in the genome, is rare
among these STs, present in only one out of 217 isolates (Figure 5).
Isolates which share four out of seven loci with ST-269 are
significantly more prevalent in carriage (48%, 91 of 187)
Figure 3. Polymorphic IGRs do not influence capsule expression or complement resistance. A: Relative amount of capsule detected by
FACS. Results are shown as mean fluorescense index (MFI; calculated as the geometric mean multiplied by the percentage of positive cells). B:
Survival in 8.33% human serum after 1 hour incubation at 37(C. Experiments were performed in duplicate on at least three independent occasions,
and error bars indicate the SD. White bars represent isogenic control strains without IS1301 in the IGR.
doi:10.1371/journal.pone.0009413.g003
IS1301 in N. meningitidis
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from other isolates in cc269 (that share five or more loci with ST-
269) of which approximately 50% have IS1301 in the IGR, with a
similar prevalence among carriage and disease isolates (Figure 5).
Therefore we excluded from our analysis all STs sharing only four
out of seven loci with ST-269. Strikingly, there was no longer a
significant difference between the presence of IS1301 in the IGR
of disease (51%; 148 out of 292) compared to carriage isolates
(49%; 47 out of 96, p=0.80).
Discussion
The presence of IS1301 in the sia/ctr IGR of MenC ST-11
enhances capsule expression and resistance against bactericidal
antibodies elicited by the MenC conjugate vaccine [6]. Although
the MenC vaccine has been successfully introduced across Europe
(with .90% efficacy [8,10]), a small number of vaccinated
individuals still develop MenC disease [11,12]. As isolates with
IS1301 in the IGR are resistant to complement, it was possible
Figure 4. Genetic relatedness between STs within cc269. Neighbor-net constructed from the concatenation of the seven MLST housekeeping
genes of N. meningitidis [4]. The major groupings (indicated with green, black, and yellow circles) represent the number of allelic differences (1, 2 and
3 respectively) from the core ST-269 allelic profile. The tree was made using the Split-Tree4 software [29].
doi:10.1371/journal.pone.0009413.g004
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isolates from people immunised with the MenC vaccine in the UK
had no evidence of IS1301 in the IGR. It is possible that these
isolates have other polymorphisms that contribute to their ability
to be virulent in the vaccinees, or that the cases have arisen
through waning host immunity rather than bacterial factors [11].
Our initial study of over 1,000 isolates from South East England
showed a highly significant association of IS1301 in the IGR
among disease versus carriage isolates. Closer examination of the
dataset showed that IS1301 in the IGR was largely restricted to
certain isolates, especially those in cc269. This is an important
clonal complex, which accounts for a substantial proportion of UK
disease cases [16,19,22]. Therefore, we examined the frequency of
the IS1301 in the IGR in a larger collection of cc269 carriage
(n=241) and disease (n=421) isolates across England and Wales,
and still observed a significant association of IS1301 in the IGR in
disease compared to carriage isolates.
Closer inspection of the IGRs with IS1301 in MenB revealed
that they are associated with novel polymorphisms. The most
frequent polymorphisms, IS-8 and iIS+69 (which account for
.80% of changes), abrogate the up-regulation of capsule
expression associated with insertion of IS1301 in MenC and do
not confer increased resistance to complement-mediated killing.
Nearly all IS1301 insertions in the original orientation [6] (99%)
identified in this study were associated with an 8 bp deletion
upstream of the siaA start. This indicates that this small deletion
influences the functional consequences of IS1301 insertion, even
though, on its own, it does not change transcriptional activity [20].
IS1301 is predicted to have two open reading frames (ORFs) [21].
It is not clear whether the 69 bp internal duplication (which is in
the second ORF of IS1301) or the orientation of the insertion
sequence is responsible for the lack of sia up-regulation in isolates
containing the iIS+69 polymorphism.
The mechanisms by which IS1301 insertion leads to up-
regulation of sia and ctr expression are not understood. Indeed,
surprisingly little is known about the genetic regulation of this key
virulence determinant, or the transcription factors that govern
expression. IS1301 could provide novel transcriptional start sites,
prevent binding of transcription factors, or change their
interaction with RNA polymerase. It is therefore interesting that
both iIS+69 and IS-8 lead to upregulation of ctr expression as in
the ST-11 isolates. This occurs regardless of the orientation of
IS1301 or its precise sequence, suggesting that increased ctr
transcription upon IS1301 insertion may result from changes in
spacing due to the additional sequence in the promoter. However,
sia expression was not elevated in either iIS+69 or in IS-8. The
reasons for this are unknown and are under further investigation.
The association of polymorphisms with IS1301 in cc269 MenB
suggests that increased expression of capsule might lead to a
significant loss of fitness in these strains, in contrast to MenC ST-
11 isolates. The reason for this apparent difference between the
two groups of isolates is not obvious. However, it is interesting to
note that isolates belonging to ST-11 are rarely found in carriage
studies, and when they are present in the nasopharynx, are more
likely to express a polysaccharide capsule than other carriage
isolates [14].
Isolates from certain STs such as 275, 1161 and 1163 were
remarkable as less than 2% have IS1301 in the IGR or anywhere
in their genome. While these isolates have been assigned to cc269,
they only share four out of seven MLST loci with ST-269 and
appear to constitute a divergent cluster, centred around ST-275.
Presence of IS1301 in the genome and sequence comparison of
vaccine candidates among cc269 isolates supports that these
isolates form or are part of a clonal complex that is distinct from
cc269 [22].
Attempts are being made to identify virulence determinants by
comparing the frequency of genetic traits between disease and
carriage isolates [23,24]. In this study we were only alerted to
potential confounding effects by the lack of increased complement
resistance conferred by the common IGR changes found in MenB
isolates. This demonstrates that even minor associated polymor-
phisms or sequence variation within genetic traits might have a
major influence on their effect. Our findings also indicate that
meaningful epidemiological comparisons of disease and carriage
populations can only be obtained by matching for individual STs,
and not at the level of clonal complex, especially when the traits
being examined do not confer an observable phenotype. This is a
major challenge, as it requires extensive collections that include
sufficient numbers of relevant STs. Such large-scale prospective
studies are needed to serve as a valuable resource.
Figure 5. Presence of IS1301 in the IGR of carriage isolates and disease isolates. Carriage (C) and disease (D) isolates were analysed for the
presence of IS1301 in the IGR depending on the numbers of loci the STs share with ST-269. Black bars represent strains with IS1301 in the IGR and
white bars show the frequency of isolates without IS1301 in the IGR. Numbers above bars indicate the total number of isolates.
doi:10.1371/journal.pone.0009413.g005
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Bacterial Strains and Growth Conditions
MenC conjugate vaccine failure strains were recovered from 33
patients in the UK who had completed a course of immunisation
yet contracted meningococcal disease [11]. All disease isolates
were obtained from sterile sites of patients from the UK with
invasive meningococcal disease from 1998 to 2007. Carriage
isolates were collected in November and December in 1999 and
2001 among 15- to 19-year old students in seven centres in the
UK: Bangor, Cardiff, Glasgow, Nottingham, Plymouth, Stockport
and Oxfordshire [18,25]. A MenB ST-269 disease isolate without
changes in the IGR, D157 (Meningococcal Reference Unit
number M01.241107), was used for construction of isogenic
strains. Escherichia coli was used for construction of the nmb76
mutant and translational fusions.
N. meningitidis was grown on Brain Heart Infusion (BHI) medium
with 5% Levanthal’s supplement at 37uC in 5% CO2; kanamycin
(kan) was used at 100 mg/ml and erythromycin at 2 mg/ml. E. coli
was grown on Luria-Bertani (LB) broth with 50 mg/ml of kan or
200 mg/ml of erythromycin, as required.
Molecular Methods
The presence of IS1301 in the IGR and the genome was
detected as described previously [6]. Primers used for PCR of the
IGR were used for DNA sequencing. To make isogenic strains,
isolates were tagged with an antibiotic marker as shown in
Figure 1B. Nmb76 was inactivated by in vitro Tn5 transposition.
Primers NG1494-for with a BamHI site (59-CTATGGGATCC-
GATTTTGACTTATGCACACACCA-39), and NG1495-rev
with an NheI site (59-GATCGCTAGCGGAAGCTATTT-
TCTCTTTATTACCG-39) were used to amplify nmb76 from
MC58. The PCR product was purified, digested with BamHI and
NheI, and ligated into pTrcHis (Invitrogen) lacking a kan resistance
cassette. The resulting vector was subjected to in vitro mutagenesis
(EPICENTRE); PCR and DNA sequencing verified insertion of
Tn5 at nucleotide 722 of nmb76. The nmb76 construct was
transformed into D157 (generating D157nmb76), a strain
(M99.240027) with an intact IS1301 in the IGR with an 8 bp
deletion (IS-8), and a strain (M99.240335) with an inverted IS1301
with an internal 69 bp duplication (iIS+69, Figure 1AB). Genomic
DNA from the tagged strains was used to transform D157 to kan
resistance. Depending on the site of the cross-overs, transformants
did (IS-8+ and iIS+69+) or did not (IS-8– and iIS+69–) contain
IS1301 in the IGR.
For RNA isolation, bacteria were grown in liquid BHI to mid-
logarithmic phase and RNA was extracted from 2610
8 cells with
the RNeasy kit (QIAGEN). Transcript levels of ctrA and siaA were
compared to levels of gdh [6]. Results were analysed by
comparative quantitation (Rotor-Gene Analysis Software, version
6.0, Corbett Research). RNA was isolated on two different
occasions and transcript levels determined twice for each sample.
SiaA Translational Fusions and b-Galactosidase Aassays
LacZ translational fusions were constructed in pUC19. The
erythromycin resistance cassette was amplified from pYHS1882
using NG1304 (59-GATTAGACGTCCACCGTGTGCTCTAC-
GAC-39) and NG1305(59-GGCAGCCCAGGGGACCATATGT-
CACAAAAAATAG-39). The PCR product was digested with AatII
and EcoO1091 and ligated into pUC19. The construct was digested
with BsaI and AatII and ligated with a 589 bp siaA fragment (nt. 571
to 1160), amplified using primers NG1306 (59-GCA-
GACGTCGCCTAGTGCAAATGGGAGAA-39) and NG1307
(59-gcaggtctcatctgtgctggtgcgagtatc). Promoters were amplified with
primers NG1324 (59-TCTGGTAAAGCTTATGCAAAGAAT-
TCT-39) and NG1419 (59-GCACATGTCATACGCACAC-
TATTCC-39) then inserted into the resulting plasmid following
digestion with HindIII and AflIII. A construct without an IGR (nt. -
597 to -206), amplified with NG1419 and NG1420 (59-
AGAAGCTTTCAG TTATTATATAAGGC-39), was used as
negative control. The lacZa fragment in pUC19 was removed by
digestion with HindIII and SfoI, and replaced with a full-length copy
of lacZ amplified from pRWX using NG1480 (59-GGATT-
CAAGCTTCGTCGTTTTACAAC-39) and NG1484 (59-
AACCGGGCGCCCAAAAGTTTGTG-39) [26].
For b-galactosidase assays, 10
9 cells were inoculated into 10 ml
of BHI and grown to mid-logarithmic phase. Cells were
centrifuged and washed twice with phosphate buffered saline
(PBS). b-galactosidase assays were performed as described
previously [27]. Miller units of enzyme activity were calculated
using the following equation: Miller Units =10006
[(OD42021.756OD550)]/(T6V6OD600), where T = reaction
time (min) and V = volume of cells added to the reaction (ml).
The values are the average of at least three experiments.
FACS Analysis
Strains were grown overnight on BHI plates and 2610
9 cells
were fixed in 3% paraformaldehyde for 1 hr, and washed three
times with PBS. Bacteria (2610
8 cells) were incubated with 1/10
dilution of serogroup B anticapsular antibody (NIBSC, code 95/
750) for 30 min at 37uC. Cells were washed twice in PBS/0.1%
Tween 20 (PBS-T), resuspended in PBS containing a FITC-
conjugated donkey anti-mouse polyclonal antibody (1:200 dilu-
tion; Jackson Immuno-Research Laboratories), and incubated for
30 min at 4uC in the dark. Samples were washed with PBS-T and
fluorescence was measured using an analyzer (FACSCalibur;
Becton Dickson), recording at least 10
4 events. Results were
calculated as mean fluorescence index (MFI) [6], which is the
geometric mean multiplied by the percentage of positive cells.
Serum bactericidal assay (SBA) and human serum assay.
Bacteria were grown overnight on solid medium. For SBAs, 10
4
cells were incubated for 1 hr at 37uC with serial dilutions of heat-
inactivated sera in the presence of 1/12 dilution of baby rabbit
complement (Pelfreeze). Cells were plated on solid media and the
SBA titres expressed as the reciprocal of the final dilution giving
(50% killing compared to controls without complement or without
sera. For serum assays, 10
5 cells were incubated in DMEM with
serial dilutions of serum from healthy volunteers for 1 hr at 37uC.
Controls were incubated with DMEM media only or with heat-
inactivated sera. Survival was calculated by counting the number
of bacteria in the input and following incubation in human serum.
Significant differences were examined with Student’s t test.
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